Yuyu Pharma Achieves Double-Digit Growth in Q1 Results... Operating Profit Up 53%

Sales of 27.1 Billion Won and Operating Profit of 4.9 Billion Won on a Standalone Basis

Profitability Improved Through Production Efficiency... Expansion of Companion Animal Business Underway

Yuyu Pharma announced on May 15 that, on a standalone basis, it recorded sales of 27.1 billion won, operating profit of 4.9 billion won, and net profit of 3.9 billion won in the first quarter of this year.

Facility view under Yuyu Pharma. Yuyu Pharma

Compared to the same period last year, sales increased by 19.4%, operating profit by 53.5%, and net profit by 59.2%, respectively.

The company stated that it is improving profitability by streamlining its production processes, while also expanding its companion animal business, which it is fostering as a new growth engine.

The shareholder return policy will also continue. Yuyu Pharma explained that it plans to complete the cancellation of its treasury shares within the first half of the year and promote an increase in dividends, aiming for separate taxation on high dividends.

Park Noyong, CEO of Yuyu Pharma, said, "We will continue to achieve profitable management this year by improving the operating margin through production process efficiency and ensuring the stable establishment of our companion animal business."

This content was produced with the assistance of AI translation services.